DIADIA0.59%
SPYSPY0.78%
QQQQQQ1.22%
Trending
Top trending tickerSMCISMCI9.18%
QQQQQQ1.22%
ORCLORCL3.32%
SPYSPY0.78%
RIVNRIVN1.02%
SLVSLV2.35%
MSFTMSFT1.32%
WLFIWLFI4.97%
ACHRACHR1.50%
VGVG0.80%
Top trending tickerSMCISMCI9.18%
QQQQQQ1.22%
ORCLORCL3.32%
SPYSPY0.78%
RIVNRIVN1.02%
SLVSLV2.35%
MSFTMSFT1.32%
WLFIWLFI4.97%
ACHRACHR1.50%
VGVG0.80%
homeSymbolFULCnews
FULC logo

FULCFulcrum Therapeutics Inc

$3.36
$0.16
(4.54%)
Pre-Market
Updated: 04:41 AM EDT·Prev Close $3.52
EarningsJul 29
Mkt Cap$229.22M
Vol1,416.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
News Placeholder
More News
News Placeholder
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged tosubmit their information immediately. You may also...
Business Wire
News Placeholder
What's Going On With Fulcrum Therapeutics Stock On Thursday?
Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.read more...
Benzinga
News Placeholder
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
Zacks
News Placeholder
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations PR Newswire NEW YORK, June 3, 2026 SEC filings reflected...
PR Newswire
News Placeholder
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
Stocktwits
News Placeholder
Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) PR...
PR Newswire
News Placeholder
FULC Stock Crashes After Hours: What Investors Need To Know
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.read more...
Benzinga
News Placeholder
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk
Fulcrum discontinued development of its lead candidate, pociredir, for sickle cell disease.
Stocktwits
News Placeholder
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.